Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology

• P. García Alfonso ^[1] ; R. García Carbonero ^[2] ; J. García Foncillas ^[3] ; P. Pérez Segura ^[4] ; R. Salazar ^[6] ; R. Vera ^[7] ; S. Ramón y Cajal ^[8] ; J. Hernández Losa ^[8] ; S. Landolfi ^[8] ; E. Musulén ^[9] ; M. Cuatrecasas ^[10] ; S. Navarro ^[5]
  1. [1] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  2. [2] Hospital Universitario 12 de Octubre

     Hospital Universitario 12 de Octubre

     Madrid, España

     
  3. [3] Fundación Jiménez Díaz

     Fundación Jiménez Díaz

     Madrid, España

     
  4. [4] Hospital Clínico San Carlos de Madrid

     Hospital Clínico San Carlos de Madrid

     Madrid, España

     
  5. [5] Hospital Clinico Universitario de Valencia

     Hospital Clinico Universitario de Valencia

     Valencia, España

     
  6. [6] Departament of Medical Oncology, ICO L’Hospitalet, Oncobell Program (IDIBELL), CIBERONC, Hospitalet de Llobregat, Spain
  7. [7] Departament of Medical Oncology, Complejo Hospitalario de Navarra; Navarrabiomed, IDISNA, Pamplona, Spain
  8. [8] Department of Pathology, Hospital Universitario Vall D’Hebron, CIBERONC, Barcelona, Spain
  9. [9] Department of Pathology, Hospital Universitari General de Catalunya, Grupo Quirónsalud, Sant Cugat del Vallès, Spain
  10. [10] Department of Pathology, Hospital Clinic, CIBERehd, Barcelona, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 11, 2020, págs. 1976-1991
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • In this update of the consensus of the Spanish Society of Medical Oncology (Sociedad Española de Oncología Médica—SEOM) and the Spanish Society of Pathology (Sociedad Española de Anatomía Patológica—SEAP), advances in the analy-sis of biomarkers in advanced colorectal cancer (CRC) as well as susceptibility markers of hereditary CRC and molecular biomarkers of localized CRC are reviewed. Recently published information on the essential determination of KRAS, NRASand BRAF mutations and the convenience of determining the amplification of human epidermal growth factor receptor 2 (HER2), the expression of proteins in the DNA repair pathway and the study of NTRK fusions are also evaluated. From the pathological point of view, the importance of analysing the tumour budding and poorly differentiated clusters, and its prog-nostic value in CRC is reviewed, as well as the impact of molecular lymph node analysis on lymph node staging in CRC. The incorporation of pan-genomic technologies, such as next-generation sequencing (NGS) and liquid biopsy in the clinical management of patients with CRC is also outlined. All these aspects are developed in this guide, which, like the previous one, will remain open to any necessary revision in the future.